Pharmacovigilance: Betamimetic drug exposure in pregnancy enhances cardiovascular disease risk of offspring

Cristina Maggioni, Germaine G Cornelissen-Guillaume, Elena V. Syutkina, Dana E Johnson, Franz Halberg

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The circadian amplitude of neonatal blood pressure, monitored for 2 days at 30-minute intervals during the first week of life on 39 babies exposed in utero to betamimetics, was statistically significantly larger than that of the 126 unexposed babies. The respective circadian double amplitudes (± SEM) were 7.9 ± 0.8 vs. 5.6 ± 0.3 mm Hg for systolic blood pressure (P=0.005) and 5.7 ± 0.6 vs. 4.0 ± 0.2 mm Hg for diastolic blood pressure (P = 0.020). An above-threshold circadian amplitude of blood pressure being associated with an increased cardiovascular disease risk, the results, corroborated independently during adolescence, warrant caution in prescribing betamimetics to prevent premature labor.

Original languageEnglish (US)
Pages (from-to)102-104
Number of pages3
JournalNeuroendocrinology Letters
Volume24
Issue numberSUPPL. 1
StatePublished - Nov 25 2003

Keywords

  • Betamimetics
  • Blood pressure
  • Cardiovascular disease risk
  • Circadian amplitude
  • Neonate
  • Offspring
  • Pregnancy
  • Premature labor

Fingerprint Dive into the research topics of 'Pharmacovigilance: Betamimetic drug exposure in pregnancy enhances cardiovascular disease risk of offspring'. Together they form a unique fingerprint.

Cite this